NanoViricides, Inc. (NNVC)
Automate Your Wheel Strategy on NNVC
With Tiblio's Option Bot, you can configure your own wheel strategy including NNVC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NNVC
- Rev/Share 0.0
- Book/Share 557769.0176
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 4.4288
- ROIC -0.0
- MktCap 18225797.0
- FreeCF/Share -187800.0858
- PFCF -0.0
- PE -2.434
- Debt/Assets 0.0
- DivYield 0
- ROE -0.0
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NNVC | Alliance Global Partners | -- | Buy | -- | -- | Dec. 16, 2025 |
News
NanoViricides advances measles drug development amid rising US cases
Published: April 29, 2025 by: Proactive Investors
Sentiment: Positive
NanoViricides (NYSE-A:NNVC) said it is moving forward with the development of a drug to treat measles, as US health officials report a continuing rise in infections amid declining vaccination rates. The Shelton, Connecticut-based biotechnology firm said it has completed propagation of the measles virus in its biosafety level-2 virology lab and is preparing to conduct an animal model study to test its clinical-stage antiviral candidate NV-387.
Read More
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
Published: April 29, 2025 by: Accesswire
Sentiment: Neutral
SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides further details on its Measles drug development program herewith.
Read More
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative
Published: March 28, 2025 by: Proactive Investors
Sentiment: Positive
The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the agency said last week. The program will prioritize novel treatments and improved diagnostics for poultry, along with vaccine development.
Read More
Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold
Published: February 21, 2025 by: Proactive Investors
Sentiment: Neutral
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
Published: February 19, 2025 by: Proactive Investors
Sentiment: Positive
NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is planning to accelerate its development pipeline, focusing on MPox treatment in Central Africa, viral acute respiratory infections, and a potential pediatric RSV indication.
Read More
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387
Published: February 11, 2025 by: Proactive Investors
Sentiment: Positive
NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to remain effective against the H5N1 virus, even as the virus undergoes rapid mutations.
Read More
About NanoViricides, Inc. (NNVC)
- IPO Date 2005-10-26
- Website https://www.nanoviricides.com
- Industry Biotechnology
- CEO Anil R. Diwan
- Employees 7